|Videos|February 9, 2022
INSPIRE and IMvigor011 Trials
Jason Starr, DO, discusses the INSPIRE and IMvigor011 studies that focused on the use of ctDNA in MRD.
Advertisement
Episodes in this series
Advertisement
Related Content
Advertisement
Advertisement
Advertisement
Trending on AJMC
1
Daraxonrasib Clears FDA as First RAS-Targeted Pancreatic Cancer Drug
2
As GLP-1 Costs Climb, Medicare Part D Plans Face a Reckoning
3
ACO-SWITCH to Evaluate Tafamidis-to-Acoramidis Switch in ATTR-CM
4
FAQ: Prior Authorization Reform—Will Changes Go Far Enough by 2027?
5